Vital capacity and inspiratory capacity as additional parameters to evaluate bronchodilator response in asthmatic patients: a cross sectional study

Karen S Azevedo1*, Ronir R Luiz2, Patricia RM Rocco3 and Marcus B Conde4

Abstract

Background: Bronchodilator response in patients with asthma is evaluated based on post-bronchodilator increase in forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). However, the need for additional parameters, mainly among patients with severe asthma, has already been demonstrated.

Methods: The aim of this study was to evaluate the usefulness of vital capacity (VC) and inspiratory capacity (IC) to evaluate bronchodilator response in asthma patients with persistent airflow obstruction. The 43 asthma patients enrolled in the study were stratified into moderate or severe airflow obstruction groups based on baseline FEV1. All patients performed a 6-minute walk test before and after the bronchodilator (BD). A bipolar visual analogue scale post-BD was performed to assess clinical effect. The correlation between VC and IC and clinical response, determined by visual analogue scale (VAS) and 6-minute walk test (6MWT), was investigated.

Results: Patients in the severe group presented: 1) greater bronchodilator response in VC (48% vs 15%, p = 0.02), 2) a significant correlation between VC variation and the reduction in air trapping (Rs = 0.70; p < 0.01), 3) a significant agreement between VC and VAS score (kappa = 0.57; p < 0.01). There was no correlation between IC and the reduction in air trapping or clinical data.

Conclusions: VC may be a useful additional parameter to evaluate bronchodilator response in asthma patients with severe airflow obstruction.

Keywords: Vital capacity, Air trapping, Hyperinflation, Asthma, Bronchodilator response

Background

Asthma is a serious worldwide health issue, but its clinical manifestations can be controlled with appropriate treatment [1]. Currently, a positive bronchodilator response is established based on an increase ≥12% and 200 ml in forced expiratory volume in one second (FEV1) compared with baseline values following administration of bronchodilators [2]. However, in clinical practice, patients with moderate or severe asthma may refer clinical improvement after bronchodilator use despite a negative bronchodilator test. In patients with chronic obstructive pulmonary disease (COPD), in whom the bronchodilator test is frequently negative, vital capacity (VC) and inspiratory capacity (IC) variation are used as complementary tools in order to evaluate bronchodilator response [3-6]. COPD patients have a persistent airway obstruction that may also be observed in moderate or severe asthma; however, only a few studies so far have evaluated the usefulness of VC and IC to assess bronchodilator response among asthmatic patients [7-13].

The aim of this study was to analyze the usefulness of VC and IC as additional parameters to assess bronchodilator response in asthma patients with moderate or severe airflow obstruction.
Methods
This study prospectively enrolled patients aged 15 years and older diagnosed with asthma and persistent airway obstruction according to Global Initiative for Asthma (GINA) criteria, and who were clinically stable at the time of enrollment [14]. Subjects were not eligible if they were current or former smokers (≥ 20 packs) or had clinical and/or radiographic evidence of heart failure, uncontrolled systemic arterial hypertension, pregnancy, focal fibrous scarring on chest X-ray with total area ≥ 1 pulmonary lobe, chest wall deformity or articular or neuromuscular disease, morbid obesity or previous lung resection. Also excluded were patients who used short-acting β2-agonist spray, long-acting β2-agonist spray or oral theophylline 8 h, 12 h or 48 h respectively before the pulmonary function tests, and patients experiencing an asthma crisis or exacerbation during the week before the pulmonary function tests. All patients were referred from the Outpatient Asthma Clinic at the Federal University of Rio de Janeiro Institute of Thoracic Diseases (ITD). They were evaluated at the ITD Pulmonary Function between June 19, 2006 and July 30, 2008. Written informed consent was obtained from all participants (or a legally responsible representative when applicable) and the study was approved by the Federal University of Rio de Janeiro Ethics Committee.

All patients answered a standardized interview and underwent physical examination as well as lateral decubitus and posteroanterior chest X-ray before the bronchodilator test [14]. Pulmonary function tests (PFTs) and a 6-minute walk test (6MWT) were performed before and 15 minutes after the bronchodilator test. Only one 6MWT was done before and after the bronchodilator. A bipolar visual analogue scale (VAS) was used to assess the perceived effect of the bronchodilator test on shortness of breath. The bronchodilator test was performed with salbutamol/400 μg spray under physician supervision (KRSA). PFTs included flow-volume and flow-time curves, inspiratory slow vital capacity maneuver and determination of static lung volumes using a Jaeger spirometer (model MasterScreen-PTF, Hoechberg, Germany), and were conducted according to American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines [15,16]. Static lung volumes were calculated using the closed-circuit helium dilution method. For He-derived TLC, the end-of-test criterion (equilibration) was defined as helium concentration change of 0.02% or less during 30s re-breathing. The predicted normal values for spirometry and lung volumes were those of Knudson et al. [17]. Polgar/Promadhat and Goldman/Becklake [18,19] respectively. The 6MWT was performed following ATS guidelines, with dyspnea score based on a Borg scale [20]. For the VAS, patients were asked to indicate on a 100 mm horizontal line, labeled “very much worse” on the left end (−100), “very much better” on the right end (+100) and “no change” (zero) in the middle, after the bronchodilator test [21]. Bronchodilator response was defined as an increase in FEV1 or FCV ≥12% of the baseline value plus 200 ml [2], or a decrease in residual volume (RV) ≥20% of the predicted value and 300 ml compared with baseline [22]. Clinical bronchodilator response was defined as 6MWD ≥50 meters or at least 30 meters associated with a reduction greater than 2 points in the Borg scale score [5,20], or any positive value in VAS. For VC and IC, an increase ≥12% and 200 ml compared with baseline indicated a positive bronchodilator test.

Asthma patients were stratified into two groups according to the value of FEV1: moderate (60% < FEV1 < 80% of predicted values) and severe airflow obstruction (FEV1 ≤60% of the predicted values), according to GINA criteria [14].

Statistical analysis
The Mann–Whitney test was used for quantitative data, and the chi-square test for qualitative parameters. The correlation between the variation in VC and IC and the variation in residual volume-to-total lung capacity ratio (RV/TLC) was analyzed using Spearman’s correlation test. The agreement between VC and IC responses and clinical response was analyzed using the Kappa coefficient. The classification proposed by Chan and Byrt for the interpretation of Spearman and Kappa values respectively, was adopted [23,24]. The statistical package for the social sciences (SPSS) v. 13.0 was used, and a p < 0.05 was considered significant.

Results
During the study period, 60 subjects were screened and 43 (72%) were enrolled: 20 had moderate airflow obstruction and 23 had severe airflow obstruction. Demographic, clinical and radiological parameters are presented in Table 1. Spirometry, 6MWT, and VAS were performed in all patients, while static lung volumes were analyzed in 37 patients. Functional data for patients with moderate and severe obstruction before (Pre) and after (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2. VC, IC, FVC, and FEV1 were significantly lower (Post) the bronchodilator (BD), test are depicted in Table 2.
If considering the ATS/ERS definition of obstructive abnormalities, FEV1/VC < 5th percentile of predicted value, only 2 patients did not fulfill this criterion, although they have FEV1 values below 80%, respectively 79.3 and 69.0%.

VC response was observed in 11 (48%) patients with severe obstruction and three (15%) with moderate obstruction (p = 0.02). No significant changes were observed between the two groups in the percentage of bronchodilator response for the other parameters.

Table 1 Demographic and clinical characteristics of asthma patients

| Parameters | Moderate airflow obstruction (n = 20) | Severe airflow obstruction (n = 23) | P |
|------------|-------------------------------------|-----------------------------------|---|
| Age (years) | 50 (37–61)                          | 56 (45–65)                        | 0.32 |
| Height (cm) | 156 (152–163)                       | 156 (153–161)                     | 0.76 |
| Weight (kg) | 70.6 (58.7-78.9)                    | 67.6 (54.7-72.2)                  | 0.38 |
| Male/Female| 6/14                                | 4/19                              | 0.33 |
| Dyspnea score (Borg scale) | 0 (0–3.3)                           | 3 (0–5)                           | 0.12 |
| Treatment (Standard/Others) | 13/7                                | 20/3                              | 0.09 |

Standard treatment: regular inhaled corticosteroids and long-acting β2-agonists. 

p value – Mann Whitney test for quantitative data and Chi-square for qualitative data. Quantitative data are expressed as median (25th percentile-75th percentile).

Table 2 Pulmonary function before and after bronchodilator of asthma patients

| Parameters | % P or L | Moderate airflow obstruction (n = 20) | Severe airflow obstruction (n = 23) | P (Mann Whitney) |
|------------|----------|-------------------------------------|-----------------------------------|-----------------|
| VC         |          |                                     |                                   |                 |
| Pre-BD (%P)| 93.2     | 75.7 (67.3-85.2)                     | <0.01                            |                 |
| Post-BD (%P)| 102      | 84.9 (76.5-96.7)                     | 0.01                             |                 |
| P (Wilcoxon)| 0.01     |                                     |                                   |                 |
| IC         |          |                                     |                                   |                 |
| Pre-BD (L) | 1.94     | 1.56 (1.24-1.88)                     | 0.01                             |                 |
| Post-BD (L)| 2.1      | 1.76 (1.50-1.94)                     | 0.01                             |                 |
| P (Wilcoxon)| 0.02     |                                     |                                   |                 |
| FVC        |          |                                     |                                   |                 |
| Pre-BD (%P)| 96.2     | 76.6 (65.5-93.9)                     | <0.01                            |                 |
| Post-BD (%P)| 105.2    | 87.7 (76.8-87.7)                     | 0.02                             |                 |
| P (Wilcoxon)| <0.01    |                                     |                                   |                 |
| FEV1       |          |                                     |                                   |                 |
| Pre-BD (%P)| 68.2     | 48.8 (42.7-55.7)                     | <0.01                            |                 |
| Post-BD (%P)| 78.9     | 60.8 (51.2-65.2)                     | <0.01                            |                 |
| P (Wilcoxon)| <0.01    |                                     |                                   |                 |
| TLC        |          |                                     |                                   |                 |
| Pre-BD (%P)| 95.8     | 92.8 (82.3-105.9)                    | 0.19                             |                 |
| Post-BD (%P)| 99.2     | 95.8 (87.4-104.0)                    | 0.40                             |                 |
| P (Wilcoxon)| 0.8      |                                     | 0.4                               |                 |
| RV/TLC     |          |                                     |                                   |                 |
| Pre-BD (%P)| 108.1    | 124.8 (105.0-145.0)                  | 0.06                             |                 |
| Post-BD (%P)| 101.0    | 111.0 (91.9-125.4)                   | 0.18                             |                 |
| P (Wilcoxon)| 0.1      |                                     | <0.01                            |                 |
| RV         |          |                                     |                                   |                 |
| Pre-BD (%P)| 105.2    | 113.0 (103.3-145.4)                  | 0.42                             |                 |
| Post-BD (%P)| 97.3     | 102.6 (87.6-124.3)                   | 0.39                             |                 |
| P (Wilcoxon)| 0.3      |                                     | 0.05                              |                 |

BD = bronchodilator, FEV1 = forced expiratory volume in one second, FVC = forced vital capacity, IC = inspiratory capacity, L = liters, P = predicted, RV = residual volume, TLC = total lung capacity, VC = vital capacity. Results are expressed as median (25th percentile-75th percentile). p value for paired sample – Wilcoxon test.
The correlations between the variation in spirometric parameters and the variation in RV/TLC (% predicted values) before and after BD were performed and we observed a significant negative correlation between VC and RV/TLC in the severe airflow obstruction group [Spearman rank correlation coefficient (Rs) = −0.70, \( p < 0.01 \)], and between FVC and RV/TLC in patients with moderate obstruction (Rs = −0.55, \( p = 0.03 \)). Conversely, there was no correlation between IC and RV/TLC. Agreement analyses for functional and clinical parameters after BD use are presented in Table 4. There was a fair agreement between VC (severe group) and FVC (moderate group) response and VAS scores, and a slight agreement between RV response (severe group) and VAS score. There was no agreement between functional parameter responses and improvement in 6MWT. There was a poor correlation (\( p = 0.35 \)) between variations in VC versus variation in VAS in severe obstruction patients, and between IC and VAS (\( p = 0.28 \)) in moderate group.

Five patients with positive VC and/or IC response presented a negative FVC and/or FEV\(_1\) response.

**Discussion**

In the present study with asthma patients with moderate and severe obstruction, we observed that VC may be a useful complementary parameter to FVC and FEV\(_1\) to assess bronchodilator response.

Asthma patients were assigned to a moderate or severe airflow obstruction group based on FEV\(_1\) analysis. In addition, because clinical improvement is the main goal of asthma therapy, VAS (subjective criterion) and 6MWT (objective criterion) were also used to evaluate clinical bronchodilator response in this study [20,21,25]. Paré et al. have described two patterns of response to bronchodilator therapy: predominant increase in expiratory flow rate (flow responders) or FVC (volume responders). Volume responders presented lower expiratory flows and greater degree of air trapping [7]. Newton et al., also reported similar results [22]. More recently, Sorkness et al., studying 287 patients with stable but severe asthma, demonstrated that this group presented prominent air trapping in contrast to individuals with non-severe asthma [12]. Our patients with severe airflow obstruction had both greater VC response in the group and greater air trapping (Table 2).

The 6MWT is considered a good parameter to estimate exercise tolerance in patients with moderate or severe pulmonary impairment, even though it has not been extensively used in asthma patients [20]. In our patients a significant increase in 6WTD as well as a decrease in Borg scale were observed in both groups (Table 3). We made only one 6MWT before and after BD use.

### Table 3 6-minute walk test results before and after bronchodilator of asthma patients

| Parameters | Moderate airflow obstruction (n = 20) | Severe airflow obstruction (n = 23) | \( P \) (Mann Whitney) |
|------------|------------------------------------|-----------------------------------|------------------------|
| 6WTD Pre-BD (m) | 515 (479–570) | 501 (468–537) | 0.26 |
| Post-BD (m) | 555 (511–588) | 519 (480–570) | 0.26 |
| P (Wilcoxon) | <0.01 | <0.01 | |
| Borg Scale Pre-BD | 5 (0–6) | 5 (3–7) | 0.35 |
| Post-BD | 3 (0–5) | 3 (1–4) | 0.86 |
| P (Wilcoxon) | 0.03 | <0.01 | |

6WTD = 6 minute walk test distance, m = meters, BD = bronchodilator. Results are expressed as median (25th percentile-75th percentile). \( p \) value for paired sample Wilcoxon test.

### Table 4 Analysis of agreement between functional and clinical positive responses after bronchodilator use

| Parameters | Moderate airflow obstruction (n = 20) | Severe airflow obstruction (n = 23) | Moderate airflow obstruction (n = 20) | Severe airflow obstruction (n = 23) |
|------------|------------------------------------|-----------------------------------|------------------------------------|-----------------------------------|
| VC | 0.20 (0.14) | 0.57 (<0.01) | 0.17 (0.39) | 0.13 (0.54) |
| IC | 0.10 (0.61) | 0.22 (0.17) | −0.33 (0.14) | −0.15 (0.47) |
| FVC | 0.40 (0.03) | 0.34 (0.06) | 0.00 (1.0) | 0.04 (0.86) |
| FEV\(_1\) | 0.10 (0.65) | 0.06 (0.75) | −0.05 (0.80) | −0.05 (0.83) |
| RV | 0.10 (0.61) | 0.32 (0.04) | 0.20 (0.37) | 0.12 (0.55) |

6MWT = six-minute walk test, FEV\(_1\) = forced expiratory volume in one second, FVC = forced vital capacity, IC = inspiratory capacity, RV = residual volume, VAS = visual analogue scale, VC = vital capacity. Results are expressed as Kappa coefficient and \( p \) value in parenthesis.
the BD because the reproducibility of the 6MWD has been considered excellent [20].

The post-BD response of VC was well correlated with the variation in RV/TLC ratio in the severe obstruction group. In this line, O’Donnell et al. studied 84 patients with obstructive disease without response in FEV1 and found a good correlation between variation in VC and IC and FRC after use of bronchodilator [6]. Additionally, Newton et al. demonstrated that lung volume improvement was independent of changes in maximal expiratory flows in patients with moderate and severe hyperinflation [22].

Agreement between VAS scores and functional responses was statistically significant in only three parameters, VC and RV in the severe obstruction group and FVC in the moderate obstruction group, without agreement with IC response (Table 4). This is in accordance with previous studies reporting a better correlation between dyspnea and the volume of thoracic gas rather than FEV1 [9,10,13]. A poor correlation (p = 0.35) was observed between variations in VC versus variation in VAS in severe obstruction patients. Probably, the reduction in air trapping is not enough to improve exertional breathlessness without a simultaneous and marked decrease in end-expiratory lung volume. Moreover, the increase in VC and IC may represent unrelated effects of the bronchodilation. VAS has been shown to be sensitive to detect improvement in asthma patients [26].

FEV1 is considered a good marker of improvement. However, in patients with severe airflow obstruction, FEV1 presents a lack of sensitivity and is a poor predictor of improvement in exercise tolerance [22,27-29]. Moreover, Teeter and colleagues demonstrated that asthma symptoms were poorly correlated with FEV1 before and after therapy [30]. Therefore, in addition to FEV1, other physiologic parameters, such as lung elastic recoil, should be considered to characterize asthma severity [31].

This study has some limitations that need to be addressed: 1) we were not able to correlate the reduction in air trapping with the increase in IC measured in rest, as previously described during exercises tests [3,9,29] or during methacholine challenge testing [8,11] and 2) static lung volumes were measured using the helium dilution method, even though body plethysmography is considered the most sensitive method [25,32]. However, we opted to use more routine tests because ergospirometry, bronchoprovocation test and plethysmography are not available in most pulmonary function laboratories.

Conclusions

The present findings suggest that VC may be useful in addition to FVC and FEV1 to identify bronchodilator response in asthma patients with severe airflow obstruction.

Competing interests

The authors declare that they have no competing of interests.

Authors’ contributions

KA conceived of the study, and participated in data collection and data analysis and wrote the manuscript. RL participated in the design of the study and the statistical analysis. PR and MC participated in its design and coordination, contributed to data interpretation and writing the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Fundoção de Amparo a Pesquisa do Estado do Rio de Janeiro- FAPERJ (E26/ 101.491/2010 to M Conde).

The authors would like to express their gratitude to Prof. Roberto Bravo de Souza for his suggestions, Mr. Arthur Miranda Júnior for his skillful technical assistance during pulmonary function tests and Mrs. Claudia Buchweitz for her assistance in editing the manuscript.

Author details

1Laboratory of Pulmonary Function Tests, Institute of Thoracic Diseases, Federal University of Rio de Janeiro, Praça Jorge Machado Moreira 100, Federal University of Rio de Janeiro, Brazil. 2Institute of Public Health Studies, Federal University of Rio de Janeiro, Praça Jorge Machado Moreira 100, Federal University of Rio de Janeiro, Brazil. 3Laboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Cidade Universitária – CCS, CEP 21941-902, Rio de Janeiro, Brazil. 4Institute of Thoracic Diseases, Federal University of Rio de Janeiro, Rua Professor Rodolfo Paulo Rocco, 255/6º andar, Cidade Universitária, CEP 21941–913Rio de Janeiro, Brazil.

Received: 29 November 2011 Accepted: 23 August 2012

References

1. Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention. NHLBI / WHO Workshop Report. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2009.
2. Pellegrino R, Viegi G, Brusasco R, Crapo R, Burgos F, Casaburi R, Coates A, Van Der Gelinen MP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J 2005, 26:504–68.
3. O’Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 158:1357–1365.
4. Tartucci C, Duguet A, Similowski T, Zelter M, Derenne J-P, Milic-Emili J. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998, 12:799–804.
5. Rodrigues JR, Pereira CAC. Resposta a broncodilatador na espirometria: que parâmetros e valores são clinicamente relevantes em doenças obstrutivas? J Pneumol 2000, 27:35–47.
6. O’Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patient with “inversible” emphysema. Eur Respir J 2001, 18:914–920.
7. Park PD, Lawson LM, Brooks LA. Patterns of response to inhaled bronchodilators in asthmatics. Am Rev Respir Dis 1993, 147:680–685.
8. Lougheed MD, Lam M, Forkert L, Webb KA, O’Donnell DE. Breathlessness during acute bronchoconstriction in asthma. Am Rev Respir Dis 1993, 148:1452–1459.
9. Tartucci C, Eliafi M, Duguet A, Similowski T, Derenne J-P, Milic-Emili J. Dynamic hyperinflation and flow limitation during methacholine-induced bronchoconstriction in asthma. Eur Respir J 1999, 14:295–301.
10. Filippelli M, Duranti R, Giglioli F, Bianchi R, Grazzini M, Stendardi L, Scano G. Overall contribution of chest wall hyperinflation to breathlessness in asthma. Chest 2003, 124:2164–2170.
11. Lougheed MD, Fisher T, O’Donnell DE. Dynamic hyperinflation during bronchoconstriction in asthma. Chest 2006, 130:1072–1081.
12. Sorkness RL, Bleeker ER, Busse WW, Calhoun WU, Castro M, Chung KF, Curran- Everett D, Ezurun SC, Gaston BM, Israel E, Jarjour NN, Moore WC, Peters SP, Teague WG, Wenzel SE. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008, 104:394–403.
13. Sutherland TJ, Cowan JO, Taylor DR: Dynamic hyperinflation with bronchoconstriction. Am J Respir Crit Care Med 2008, 177:970–975.
14. Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention. NHLBI / WHO Workshop Report. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2006.
15. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, Van Der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, Mckay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: Standardisation of spirometry. Eur Respir J 2005, 26:319–338.
16. Wanger J, Clausen J, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, Van Der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, Mckay R, Miller MR, Navajas D, Pellegrino R, Viegi G: Standardisation of the measurement of lung volumes. Eur Respir J 2005, 26:511–522.
17. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B: Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983, 127:725–734.
18. Polgar G, Promadhat V: Pulmonary function testing in children. Techniques and standards. Philadelphia: WB Saunders Co; 1971.
19. Goldman HI, Becklake MR: Respiratory Function Tests. Normal values at median altitudes and the prediction of normal results. Am Rev Tuberc Pulm Dis 1959, 79:457–467.
20. American Thoracic Society: ATS Statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111–117.
21. Noseda A, Schmerber J, Prigogine T, Yernault JC: Perceived effect on shortness of breath of an acute inhalation of saline or terbutaline: variability and sensitivity of a visual analogue scale in patients with asthma or COPD. Eur Respir J 1992, 8:1043–1053.
22. Newton MF, O’Donnell DE, Forkert L: Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002, 121:1042–1050.
23. Bytt T: How good is agreement. Epidemiology 1996, 7:561.
24. Chan YH: Biostatistics 104: Correlation analysis. Singapore Med J 2003, 44:614–619.
25. Barreiro E, Gea J, Sanjuás C, Marcos R, Broquetas J, Milic-Emili J: Dyspnoea at rest and at end of different exercises in patients with near-fatal asthma. Eur Respir J 2004, 24:219–225.
26. Isakovic J, Isakovic L, Filipovic I: The correlation between the Borg score and VAS and lung function parameters in patients with asthma and COPD. In 20th Ann Cong of the European Respiratory Society (ERS), Barcelona, 18–22 sep2010, Eur Respir J, Volume 36, 2010. Suppl 54.
27. Beltman MJ, Warren C, Botnick C, Shin JW: Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996, 153:967–975.
28. O’Donnell DE, Lam M, Webb KA: Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160:542–549.
29. Kosmas EN, Milic-Emili J, Polychronaki A, Dimitroulis I, Retsou S, Gaga M, Koutsoyannopoulos A, Roussos C, Koutouris NG: Exercise-induce flow limitation, dynamic hyperinflation and exercise capacity in patients with bronchial asthma. Eur Respir J 2004, 24:378–384.
30. Teeter JG, Bleecker ER: Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest 1998, 11:272–277.
31. Wenné J: Severe asthma in adults. Am J Respir Crit Care Med 2005, 172:149–160.
32. Wanjer PH, Tammeling GJ, Cotes JE, Pederson OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for steel and coal. Official statement of the European Respiratory Society. Eur Respir J 1993, 16:5–40.

Cite this article as: Azevedo et al.: Vital capacity and inspiratory capacity as additional parameters to evaluate bronchodilator response in asthmatic patients: a cross sectional study. BMC Pulmonary Medicine 2012 12:49.